Zoledronic acid combined with chemotherapy bring survival benefits to patients with bone metastases from nasopharyngeal carcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 10, 2011, Pages 1545-1551

  Jin, Ying ^a   An, Xin ^a   Cai, Yu Chen ^a   Cao, Ye ^a   Cai, Xiu Yu ^a   Xia, Qing ^a   Tan, Yu Ting ^a   Jiang, Wen Qi ^a   Shi, Yan Xia ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Bone metastases; Chemotherapy; Nasopharyngeal carcinoma; Survival benefit; Zoledronic acid

Indexed keywords

ALKALINE PHOSPHATASE; CISPLATIN; FLUOROURACIL; PACLITAXEL; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL FEATURE; COMPARATIVE STUDY; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SPINE METASTASIS; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR NECROSIS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 80054791771     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-011-1027-8     Document Type: Article

References (36)

1. E Au PT Ang 1994 A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma Ann Oncol 5 1 87 89 8172799 1:STN:280:DyaK2c3is12hsQ%3D%3D (Pubitemid 24049859)
2. Y Bensouda W Kaikani N Ahbeddou R Rahhali M Jabri H Mrabti H Boussen H Errihani 2011 Treatment for metastatic nasopharyngeal carcinoma Eur Ann Otorhinolaryngol Head Neck Dis 128 2 79 85 21177151 10.1016/j.anorl.2010.10.003 1:STN:280:DC%2BC3Mvls1eruw%3D%3D
3. S Boissier M Ferreras O Peyruchaud S Magnetto FH Ebetino M Colombel P Delmas JM Delaissé P Clézardin 2000 Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases Cancer Res 60 11 2949 2954 10850442 1:CAS:528:DC%2BD3cXjvFOltrY%3D (Pubitemid 30395820)
4. JG Buckley A Ferlito AR Shaha A Rinaldo 2001 The treatment of distant metastases in head and neck cancer-present and future ORL J Otorhinolaryngol Relat Spec 63 4 259 264 11408825 10.1159/000055753 1:STN:280: DC%2BD3MzksFOnug%3D%3D (Pubitemid 32620181)
5. AT Chan PM Teo PJ Johnson 2002 Nasopharyngeal carcinoma Ann Oncol 13 7 1007 1015 12176778 10.1093/annonc/mdf179 1:STN:280:DC%2BD38vitFWgtg%3D%3D
6. ET Chang HO Adami 2006 The enigmatic epidemiology of nasopharyngeal carcinoma Cancer Epidemiol Biomarkers Prev 15 10 1765 1777 17035381 10.1158/1055-9965.EPI-06-0353 1:CAS:528:DC%2BD28XhtVGktbvL (Pubitemid 44664247)
7. F Chiesa F De Paoli 2001 Distant metastases from nasopharyngeal cancer ORL J Otorhinolaryngol Relat Spec 63 4 214 216 11408815 10.1159/000055743 1:STN:280:DC%2BD3MzksFOgug%3D%3D (Pubitemid 32621719)
8. DT Chua WI Wei MP Wong JS Sham J Nicholls GK Au 2008 Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma Head Neck 30 7 863 867 18213730 10.1002/hed.20792 (Pubitemid 352008945)
9. P Clezardin 2005 Anti-tumour activity of zoledronic acid Cancer Treat Rev 31 Suppl 3 1 8 16225995 10.1016/j.ctrv.2005.09.002
10. P Croucher S Jagdev R Coleman 2003 The anti-tumor potential of zoledronic acid Breast 12 Suppl 2 S30 S36 14659141 10.1016/S0960-9776(03)80161-3
11. A Ferlito AR Shaha CE Silver A Rinaldo V Mondin 2001 Incidence and sites of distant metastases from head and neck cancer ORL J Otorhinolaryngol Relat Spec 63 4 202 207 11408812 10.1159/000055740 1:STN:280:DC%2BD3MzksFOgtw%3D%3D (Pubitemid 32620169)
12. P Fournier S Boissier S Filleur J Guglielmi F Cabon M Colombel P Clézardin 2002 Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats Cancer Res 62 22 6538 6544 12438248 1:CAS:528:DC%2BD38XovFOksrk%3D (Pubitemid 35364119)
13. O Fromigue L Lagneaux JJ Body 2000 Bisphosphonates induce breast cancer cell death in vitro J Bone Miner Res 15 11 2211 2221 11092402 10.1359/jbmr.2000.15.11.2211 1:CAS:528:DC%2BD3cXnvVKltL0%3D
14. Green JR (2003) Antitumor effects of bisphosphonates. Cancer 1;97(3 Suppl):840-847 (Pubitemid 36125821)
15. JR Green 2004 Bisphosphonates: preclinical review Oncologist 9 Suppl 4 3 13 15459425 10.1634/theoncologist.9-90004-3 1:CAS:528:DC%2BD2cXpslGhtb0%3D (Pubitemid 39363164)
16. SP Jagdev RE Coleman CM Shipman HA Rostami PI Croucher 2001 The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel Br J Cancer 84 8 1126 1134 11308265 10.1054/bjoc.2001.1727 1:CAS:528:DC%2BD3MXktFymu7w%3D (Pubitemid 32448513)
17. M Jahanzeb V Hirsh 2010 Bisphosphonates in lung cancer: more than a palliative therapy? Semin Oncol 37 Supp 1 45 52 10.1053/j.seminoncol.2010.06.004
18. Kam MK, Leung SF, Zee B, Chau RM, Suen JJ, Mo F, Lai M, Ho R, Cheung K, Yu BK, Chiu SK, Choi PH, Teo PM, Kwan WH, Chan AT (2007) Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 1;25(31):4873-4879 (Pubitemid 350220416)
19. LA Kingsley PG Fournier JM Chirgwin TA Guise 2007 Molecular biology of bone metastasis Mol Cancer Ther 6 10 2609 2617 17938257 10.1158/1535-7163.MCT- 07-0234 1:CAS:528:DC%2BD2sXhtFKltbnE (Pubitemid 350058141)
20. LN Li PW Dong 2009 Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 22 2368 19484818 1:CAS:528:DC%2BD1MXmsFSgtb4%3D author reply 9-70
21. MT Liu CY Hsieh TH Chang JP Lin CC Huang AY Wang 2003 Prognostic factors affecting the outcome of nasopharyngeal carcinoma Jpn J Clin Oncol 33 10 501 508 14623917 10.1093/jjco/hyg092 (Pubitemid 43115242)
22. BB Ma AT Chan 2005 Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma Cancer 103 1 22 31 15565580 10.1002/cncr.20768 (Pubitemid 39665453)
23. JW Min SW Um JJ Yim CG Yoo SK Han YS Shim YW Kim 2009 The role of whole-body FDG PET/CT, Tc 99 m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer J Korean Med Sci 24 2 275 280 19399270 10.3346/jkms.2009.24.2.275
24. R Montague CA Hart NJ George VA Ramani MD Brown NW Clarke 2004 Differential inhibition of invasion and proliferation by bisphosphonates: anti-metastatic potential of Zoledronic acid in prostate cancer Eur Urol 46 3 389 401 15306113 10.1016/j.eururo.2004.04.022 1:CAS:528:DC%2BD2cXnvVWitb4%3D (Pubitemid 39078576)
25. HL Neville-Webbe A Rostami-Hodjegan CA Evans RE Coleman I Holen 2005 Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells Int J Cancer 113 3 364 371 15455384 10.1002/ijc.20602 1:CAS:528:DC%2BD2MXhsFSq (Pubitemid 40038702)
26. RK Ngan HH Yiu WH Lau S Yau FY Cheung TM Chan CH Kwok CY Chiu SK Au W Foo CK Law KC Tse 2002 Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study Ann Oncol 13 8 1252 1258 12181249 10.1093/annonc/mdf200 1:STN:280: DC%2BD38visVeqtw%3D%3D (Pubitemid 34960134)
27. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 20;100(16):1167-1178
28. TJ Polascik 2009 Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases Drug Des Devel Ther 3 27 40 19920919 1:CAS:528:DC%2BD1MXoslSmsLk%3D
29. AR Razak LL Siu FF Liu E Ito B O'Sullivan K Chan 2010 Nasopharyngeal carcinoma: the next challenges Eur J Cancer 46 11 1967 1978 20451372 10.1016/j.ejca.2010.04.004
30. KO Rove ED Crawford 2009 Metastatic cancer in solid tumors and clinical outcome: skeletal-related events Oncology (Williston Park) 23 14 Suppl 5 21 27
31. F Saad 2008 New research findings on zoledronic acid: survival, pain, and anti-tumour effects Cancer Treat Rev 34 2 183 192 18061356 10.1016/j.ctrv.2007. 10.002 1:CAS:528:DC%2BD1cXjtl2jtrs%3D (Pubitemid 351384327)
32. F Schindler PP Lajolo H Pinczowski FL Fonseca A Barbieri LH Massonetto FT Katto AD Giglio 2008 Bone and total alkaline phosphatase for screening skeletal metastasis in patients with solid tumours Eur J Cancer Care (Engl) 17 2 152 156 10.1111/j.1365-2354.2007.00826.x 1:STN:280:DC%2BD1c7ktlGhtg%3D%3D
33. Sonpavde G, Pond GR, Berry WR, Wit RD, Armstrong AJ, Eisenberger MA, Tannock LF (2010) Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol 29. doi: 10.1016/j.urolonc. 2010.07.002
34. EH Tan KS Khoo J Wee KW Fong KS Lee ET Chua T Tan HS Khoo-Tan TL Yang E Au M Tao YK Ong EJ Chua 1999 Phase II trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma Ann Oncol 10 2 235 237 10093695 10.1023/A:1008390929826 1:STN:280:DyaK1M7ptlKmtw%3D%3D (Pubitemid 29113186)
35. J Wood K Bonjean S Ruetz A Bellahcène L Devy JM Foidart V Castronovo JR Green 2002 Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid J Pharmacol Exp Ther 302 3 1055 1061 12183663 10.1124/jpet.102.035295 1:CAS:528:DC%2BD38XmsF2hsbc%3D (Pubitemid 34920226)
36. MC Yu JM Yuan 2002 Epidemiology of nasopharyngeal carcinoma Semin Cancer Biol 12 6 421 429 12450728 10.1016/S1044579X02000858 (Pubitemid 35370755)